Effectiveness of Mobile Health Applications for Cardiometabolic Risk Reduction in Urban and Rural India: A Pilot, Randomized Controlled Study.

IF 4.1 Q2 ENDOCRINOLOGY & METABOLISM

Journal of Diabetes Science and Technology Pub Date : 2025-01-14 DOI:10.1177/19322968241310861

Harish Ranjani, Parizad Avari, Sharma Nitika, Narayanaswamy Jagannathan, Nick Oliver, Jonathan Valabhji, Viswanathan Mohan, John Campbell Chambers, Ranjit Mohan Anjana

{"title":"Effectiveness of Mobile Health Applications for Cardiometabolic Risk Reduction in Urban and Rural India: A Pilot, Randomized Controlled Study.","authors":"Harish Ranjani, Parizad Avari, Sharma Nitika, Narayanaswamy Jagannathan, Nick Oliver, Jonathan Valabhji, Viswanathan Mohan, John Campbell Chambers, Ranjit Mohan Anjana","doi":"10.1177/19322968241310861","DOIUrl":null,"url":null,"abstract":"Introduction: mHealth technology has the potential to deliver personalized health care; however, data on cardiometabolic risk factors are limited. This study aims to assess the effectiveness of mobile health applications (apps) on cardiometabolic risk factor reduction in adults aged 25 to 60 years in urban and rural India.Methods: The study design was a pilot randomized controlled trial conducted in Tamil Nadu, India. Smartphone users (25-60 years) with basic literacy and at high risk of developing diabetes (Indian Diabetes Risk Score ≥30 and/or fasting blood sugar [FBS] 100-125 mg/dL) were recruited. Four mobile apps (two commercially available, two novel) for cardiometabolic risk reduction were evaluated. Primary outcome (weight loss) was analyzed using intention-to-treat analysis with post hoc analysis and logistic regression models adjusted for confounders.Results: A total of 5264 participants were screened, and 610 were recruited into the study. Participants (7%) dropped out largely due to the COVID-19 pandemic. Data from 567 participants were used for the final analysis. In the intention-to-treat analysis, a significant reduction in body weight was observed in the intervention group as compared with control, more so in the urban (-2.40 kg, 95% confidence interval [CI] = [-3.10, -1.69], P < .001) compared with rural population (-1.19 kg, 95% CI = [-1.55, -0.82], P < .001). Intervention group participants showed significant reductions in body mass index, waist circumference, blood pressure, FBS, total serum cholesterol, and a positive effect on dietary and physical activity behaviors compared with controls.Conclusions: mHealth interventions can reduce diabetes risk, improve cardiometabolic health, and improve lifestyle behaviors in South Asian populations.Trial registration: The trial is registered with the Central Trials Registry, India (CTRI/2020/03/024327).","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"19322968241310861"},"PeriodicalIF":4.1000,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11733870/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Diabetes Science and Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/19322968241310861","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: mHealth technology has the potential to deliver personalized health care; however, data on cardiometabolic risk factors are limited. This study aims to assess the effectiveness of mobile health applications (apps) on cardiometabolic risk factor reduction in adults aged 25 to 60 years in urban and rural India.

Methods: The study design was a pilot randomized controlled trial conducted in Tamil Nadu, India. Smartphone users (25-60 years) with basic literacy and at high risk of developing diabetes (Indian Diabetes Risk Score ≥30 and/or fasting blood sugar [FBS] 100-125 mg/dL) were recruited. Four mobile apps (two commercially available, two novel) for cardiometabolic risk reduction were evaluated. Primary outcome (weight loss) was analyzed using intention-to-treat analysis with post hoc analysis and logistic regression models adjusted for confounders.

Results: A total of 5264 participants were screened, and 610 were recruited into the study. Participants (7%) dropped out largely due to the COVID-19 pandemic. Data from 567 participants were used for the final analysis. In the intention-to-treat analysis, a significant reduction in body weight was observed in the intervention group as compared with control, more so in the urban (-2.40 kg, 95% confidence interval [CI] = [-3.10, -1.69], P < .001) compared with rural population (-1.19 kg, 95% CI = [-1.55, -0.82], P < .001). Intervention group participants showed significant reductions in body mass index, waist circumference, blood pressure, FBS, total serum cholesterol, and a positive effect on dietary and physical activity behaviors compared with controls.

Conclusions: mHealth interventions can reduce diabetes risk, improve cardiometabolic health, and improve lifestyle behaviors in South Asian populations.

Trial registration: The trial is registered with the Central Trials Registry, India (CTRI/2020/03/024327).

查看原文本刊更多论文

移动医疗应用程序在印度城市和农村降低心脏代谢风险的有效性：一项试点、随机对照研究

导言：移动医疗技术具有提供个性化医疗服务的潜力；然而，有关心脏代谢风险因素的数据却很有限。本研究旨在评估移动医疗应用程序对印度城乡地区 25 至 60 岁成年人降低心脏代谢风险因素的效果：研究设计是在印度泰米尔纳德邦进行的试点随机对照试验。研究招募了具有基本文化水平和糖尿病高风险（印度糖尿病风险评分≥30和/或空腹血糖[FBS] 100-125 mg/dL）的智能手机用户（25-60岁）。对四款降低心脏代谢风险的手机应用（两款市售，两款新颖）进行了评估。主要结果（体重减轻）采用意向治疗分析、事后分析和逻辑回归模型进行分析，并对混杂因素进行了调整：共筛选出 5264 名参与者，其中 610 人被纳入研究。主要由于 COVID-19 大流行，有 7% 的参与者退出了研究。最终分析使用了 567 名参与者的数据。在意向治疗分析中，观察到干预组与对照组相比体重显著下降，城市人口（-2.40 千克，95% 置信区间 [CI] = [-3.10, -1.69], P < .001）与农村人口（-1.19 千克，95% 置信区间 [CI] = [-1.55, -0.82]，P < .001）相比下降幅度更大。与对照组相比，干预组参与者的体重指数、腰围、血压、血脂、血清总胆固醇均有明显下降，饮食和体育锻炼行为也有积极影响。结论：移动医疗干预措施可降低糖尿病风险，改善心血管代谢健康，并改善南亚人群的生活方式：该试验已在印度中央试验注册中心注册（CTRI/2020/03/024327）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Diabetes Science and Technology Medicine-Internal Medicine

CiteScore

7.50

自引率

12.00%

发文量

148

期刊介绍： The Journal of Diabetes Science and Technology (JDST) is a bi-monthly, peer-reviewed scientific journal published by the Diabetes Technology Society. JDST covers scientific and clinical aspects of diabetes technology including glucose monitoring, insulin and metabolic peptide delivery, the artificial pancreas, digital health, precision medicine, social media, cybersecurity, software for modeling, physiologic monitoring, technology for managing obesity, and diagnostic tests of glycation. The journal also covers the development and use of mobile applications and wireless communication, as well as bioengineered tools such as MEMS, new biomaterials, and nanotechnology to develop new sensors. Articles in JDST cover both basic research and clinical applications of technologies being developed to help people with diabetes.